Nothing Special   »   [go: up one dir, main page]

TR201904655T4 - Piridilaminoasetik asit bileşiği. - Google Patents

Piridilaminoasetik asit bileşiği. Download PDF

Info

Publication number
TR201904655T4
TR201904655T4 TR2019/04655T TR201904655T TR201904655T4 TR 201904655 T4 TR201904655 T4 TR 201904655T4 TR 2019/04655 T TR2019/04655 T TR 2019/04655T TR 201904655 T TR201904655 T TR 201904655T TR 201904655 T4 TR201904655 T4 TR 201904655T4
Authority
TR
Turkey
Prior art keywords
acid compound
pyridylaminoacetic acid
pyridylaminoacetic
asthma
therapeutic
Prior art date
Application number
TR2019/04655T
Other languages
English (en)
Inventor
Iwamura Ryo
Tanaka Masayuki
Katsube Tetsushi
Shigetomi Manabu
Okanari Eiji
Tokunaga Yasunori
Fujiwara Hiroshi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201904655(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Publication of TR201904655T4 publication Critical patent/TR201904655T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Mevcut buluş, şu formül (1) ile temsil edilen yeni bir piridilaminoasetik asit bileşiği: (burada R1, R2, R3, Y ve Z, tarifname ve istemlerde tanımlanan şekildedir), veya bunun farmakolojik olarak kabul edilebilir bir tuzunu sağlamaktadır. Piridilaminoasetik asit bileşiği, EP2 agonistik eyleme sahiptir ve bu nedenle astım veya kronik obstrüktif pulmoner hastalık gibi respiratuar hastalıklar için bir terapötik ve/veya profilaktik ajan olarak yararlıdır.
TR2019/04655T 2008-03-12 2009-03-12 Piridilaminoasetik asit bileşiği. TR201904655T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008062926 2008-03-12

Publications (1)

Publication Number Publication Date
TR201904655T4 true TR201904655T4 (tr) 2019-06-21

Family

ID=41065261

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04655T TR201904655T4 (tr) 2008-03-12 2009-03-12 Piridilaminoasetik asit bileşiği.

Country Status (18)

Country Link
US (2) US8648097B2 (tr)
EP (1) EP2264009B1 (tr)
JP (3) JP5136640B2 (tr)
KR (1) KR101609001B1 (tr)
CN (2) CN101970410B (tr)
AU (1) AU2009224329B2 (tr)
CA (1) CA2718393C (tr)
CY (1) CY1121543T1 (tr)
DK (1) DK2264009T3 (tr)
ES (1) ES2718813T3 (tr)
HR (1) HRP20190509T1 (tr)
HU (1) HUE042839T2 (tr)
LT (1) LT2264009T (tr)
PL (1) PL2264009T3 (tr)
PT (1) PT2264009T (tr)
SI (1) SI2264009T1 (tr)
TR (1) TR201904655T4 (tr)
WO (1) WO2009113600A1 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904655T4 (tr) 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
EP2415763B1 (en) * 2009-03-30 2016-01-27 Ube Industries, Ltd. Pharmaceutical composition for treating or preventing glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
CA2773997A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Aniline compound
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
KR20120101722A (ko) * 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
RU2512344C1 (ru) 2010-03-12 2014-04-10 Ниппон Сода Ко., Лтд. Соединение, содержащие кольцо пиридина, и способ получения галогенированного производного пиколина и производного тетразолилоксима
AR080684A1 (es) * 2010-03-18 2012-05-02 Bayer Cropscience Ag Aril- y hetarilsulfonamidas como sustancias activas contra un estres abiotico de plantas
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
US9676720B2 (en) * 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
JPWO2015030250A1 (ja) * 2013-09-02 2017-03-02 宇部興産株式会社 肺疾患の治療及び／又は予防のための医薬組成物
ES2874547T3 (es) 2014-01-10 2021-11-05 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado
CN105828818B (zh) 2014-01-10 2020-06-02 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物组合物
US9415038B2 (en) 2014-01-10 2016-08-16 Santen Pharmaceutical Co., Ltd. Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
CN106458904B (zh) 2014-06-10 2021-12-03 宇部兴产株式会社 N-取代磺酰胺化合物及其制造方法
WO2015190506A1 (ja) * 2014-06-10 2015-12-17 宇部興産株式会社 ヘテロ芳香族スルホンアミド化合物の製造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
ES2950461T3 (es) 2015-07-09 2023-10-10 Santen Pharmaceutical Co Ltd Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen
JP7250685B2 (ja) * 2017-09-29 2023-04-03 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
US20210106569A1 (en) 2017-12-21 2021-04-15 Santen Pharmaceutical Co., Ltd. Omidenepag combination
TWI842692B (zh) 2017-12-28 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥製劑

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532701A4 (en) 1990-06-08 1993-07-14 Sps Technologies, Inc. Improved magnetic materials and process for producing the same
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
KR20040022238A (ko) 2001-08-09 2004-03-11 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
EP1438104B1 (en) 2001-10-26 2006-04-05 Allergan, Inc. Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
KR20040077884A (ko) 2002-01-31 2004-09-07 화이자 프로덕츠 인코포레이티드 （3-｛〔（4-3급-뷰틸-벤질）-（피리딘-3-설폰일）-아미노〕-메틸｝-페녹시）-아세트산의 대사산물
RU2306309C2 (ru) 2002-03-05 2007-09-20 Оно Фармасьютикал Ко., Лтд. Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
KR20050105511A (ko) 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ｅｐ2 선택적 수용체 효능제의 용도
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
EP1714961B1 (en) 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
JP4966866B2 (ja) 2005-01-14 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ５アンタゴニストとしてのチアゾール−４−カルボキサミド誘導体
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
CA2616608A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
WO2007017687A2 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
BRPI0714683A2 (pt) 2006-07-28 2013-03-26 Pfizer Prod Inc agonistas ep2
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
TR201904655T4 (tr) 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
EP2415763B1 (en) * 2009-03-30 2016-01-27 Ube Industries, Ltd. Pharmaceutical composition for treating or preventing glaucoma

Also Published As

Publication number Publication date
DK2264009T3 (en) 2019-04-15
US20140113907A1 (en) 2014-04-24
CA2718393C (en) 2015-06-16
PT2264009T (pt) 2019-04-29
EP2264009A4 (en) 2012-08-01
JP5545344B2 (ja) 2014-07-09
CA2718393A1 (en) 2009-09-17
PL2264009T3 (pl) 2019-07-31
US20110054172A1 (en) 2011-03-03
JP5136640B2 (ja) 2013-02-06
CN101970410A (zh) 2011-02-09
KR20100123903A (ko) 2010-11-25
CN101970410B (zh) 2014-06-25
US8648097B2 (en) 2014-02-11
SI2264009T1 (sl) 2019-05-31
HRP20190509T1 (hr) 2019-05-03
CN103965099A (zh) 2014-08-06
KR101609001B1 (ko) 2016-04-04
JP2013063994A (ja) 2013-04-11
JPWO2009113600A1 (ja) 2011-07-21
AU2009224329B2 (en) 2013-11-07
ES2718813T3 (es) 2019-07-04
EP2264009A1 (en) 2010-12-22
HUE042839T2 (hu) 2019-07-29
CY1121543T1 (el) 2020-05-29
LT2264009T (lt) 2019-04-25
AU2009224329A1 (en) 2009-09-17
WO2009113600A1 (ja) 2009-09-17
EP2264009B1 (en) 2019-03-06
JP2014177476A (ja) 2014-09-25

Similar Documents

Publication Publication Date Title
TR201904655T4 (tr) Piridilaminoasetik asit bileşiği.
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
GEP201706735B (en) Kinase inhibitors
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
SG166121A1 (en) Pyrimidine amide compounds as pgds inhibitors
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
GB0510584D0 (en) Organic compounds
GEP20146125B (en) Aminopyrimidines as syk inhibitors
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
GEP20156216B (en) Heterocyclic compound and usage thereof
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
UA107784C2 (en) Inhibitor of melanin production
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
JP2011500575A5 (tr)
EA201100502A1 (ru) Гликозидные производные и их применения
UA114008C2 (xx) Похідні етинілу як модулятори активності рецептора mglur5
MX2009006266A (es) Procedimientos de preparacion de 3-(4-(2,4-difluorobenciloxi)-3-br omo-6-metil-2-oxopiridin-1 (2h)-il)-n,4-dimetilbenzamida.
MX2013010006A (es) Derivados de sec-hidroxiciclohexilo como inhibidores de lipasa sensible a hormonas (hsl) para el tratamiento de diabetes.